Auto Immune Hemolytic Anemia

Aplastic Anemia is a potentially life threatening syndrome in which the affected person experiences pancytopenia which means there is a reduced production of red blood cells [RBCs], white blood cells [WBCs] as well as platelets. The affected person also will have hypoplastic bone marrow which means that fat replacement in the bone marrow space which is normally filled with hematopoietic precursor cells (Cabrera & Schiebel, 2015). The cells produced by the bone marrow are crucial for supplying oxygen and nourishment to tissues and organs, fighting off infection and clotting of

Acute Lymphoblastic Leukemia, is the disease that affects children the most and because of the abnormal cells that are immature white blood cells which cannot help the body fight infections cause children with the disease to often get infections and have fevers (National Cancer Institute, 2002, p. 1). The symptoms that the patient with ALL may have depend on the number of abnormal cells of the patient where exactly the cells collect. Children patients with ALL have low amounts of healthy red blood cells and platelets, which cause less oxygen to be carried through the body because of the lack of red blood cells. Patients at times may look pale, feel weak, and tired causing bleeding and bruising very easily because of their lack of enough platelets. This condition is called anemia. Anemia is very much common in patients with acute lymphoblastic leukemia. Fever, fatigue, bone or joint pain, tiny red spots under the skin called petechiae are a couple of symptoms that the disease ALL has. Headaches with, or without vomiting also may occur if patient happens to have abnormal cells collecting in the brain or spinal cord (National Cancer Institute, 2002 para. 2).

The anemia of acute blood loss could be described as which one of the following?

Also known as normocytic anemia. This is the most frequent type of anemia most often happening to males over 85 years old. It is a common problem that occurs to men and women over 85 years old. Symptoms include and are caused by: a reduced production of normal-sized red blood cells even though presence of hemoglobin in the red blood cells is within the standard range; an increased production of HbS as is seen in sickle cell diseases; greater destruction and loss of red blood cells; an increase in plasma volume that is not compensated by anything else; a B2 (riboflavin) deficiency; and a B6 (pyridoxine) deficiency. (Brill & Baumgardner 2000).

1. Anemia, pp. 989. Anemia is a areduction in the total number of erythrocytes in the circulating blood or a decrease in the quality or quantity of hemoglobin. Anemias commonly result from (1) impaired erythrocyte production, (2) blood loss (acute or chronic), (3)increase erythrocyte destruction, or (4) a combination of these three. sThe fundamental physiologic manifestation of anemia is a reduced oxygen-carrying capacity of the blood resulting in tissue hypoxia.

Immune-Mediated Hemolytic Anemia (IMHA) is one of the most severe autoimmune disorders that kills between 29-77% of dogs each year [1]. The disease is usually found in large and middle aged dogs. IMHA is a pathologic process that results in premature destruction of red blood cells when an immune response directly or indirectly targets red blood cells of all ages[ 2]. IMHA can be caused by various factors, but categorized in two ways. IMHA can be an idiopathic autoimmune event (primary IMHA) or associated with trigger factors (secondary IMHA) such as imbalance of immune cells caused by another underlying disease, toxin, drug, or vaccine [3]. The most common clinical signs of IMHA may be acute or chronic, depending upon the rate of hemolysis. If the patient is in a chronic state, they will have symptoms such as lethargy, jaundice, decreased physical activity, diarrhea, or discoloration of urine, which most mistake for a urinary tract infection. If there is a more rapid hemolysis occurring, the first symptom to happen may be an acute collapse from the dog [1]. Although the mortality rate of IMHA is fairly high, there are treatment options to improve tissue oxygen delivery and to suppress the immune response to prevent some of the major complications that occur with IMHA [1]. Depending on the severity of the patients IMHA, a blood transfusion may be required, but if not then most cases are treated with immunosuppressant therapy such as glucocorticoid therapy, adjunct

Yearly, around six hundred to nine hundred people are diagnosed with Aplastic Anemia within the United States. Aplastic Anemia is a autoimmune hematological disorder that causes pancytopenia which is a reduction in major blood components, namely, erythrocytes, leukocytes and platelets. This disease has been labelled as a type of bone marrow failure, that is often due to not one but a variety of disorders that occur simultaneously. Aplastic Anemia can therefore be defined as a bone marrow disorder that is often rare, non contagious, and can often be life threatening.

Instead surrounding the blood vessel lining will be red blood cells that stop because the plasma has become damaged and completely surround the vessel not allowing blood to flow through, a thrombus has now been created. Knowing how important is that your blood have enough space to transport what it is responsible for you can notice how serious and threatening this can be. Atypical HUS will effect both children and adults. This disease is yet so rare that there is not an exact number to give one person pertaining to numeric value of children and adults effected. There has been approximately one to three million cases of aHUS. The prevalence is unknown, doctors are discovering more and more cases so we know there are still so many more people out there but it is only a matter of finding them. There lied a myth that said it effected children and a very low percentage of adults founded cases proofed otherwise, aHUS has effected 59% of children and 41% of adults. So what is Atypical HUS? Hemolytic anemia and thrombocytopenia are the key components of the hemolytic and uremic stands for the renal

Autoimmune disorder results from a hyperactive immune system attacking normal tissues as if they were foreign bodies. Immunodeficiency occurs when the immune system is not as strong as normal, resulting in recurring and life-threatening infections.

Congenital dyserythropoietic anemia is a blood disorder r that is inherited and it is also present at birth. Congenital dyserythropoietic anemia is just one of the many types of anemia, which are conditions that affect the red blood cells. When a person has anemia they have a shortage of RBC’s. Red blood cells are important in maintaining homeostasis in the body. The main functions of the red blood cells are to transport oxygenated blood to the tissues of the body. With that being said, when people suffer from anemia do not get the adequate amount of oxygen to the tissues of their body. The symptoms of anemia vary from person to person, some experience weakness, while other are more fatigued (www.ghr.nih.gov). Other symptoms include pale skin, chest pains and tachycardia or fast or irregular heart rate/ beat.

The disease I chose to do my first paper on is Hemolytic Uremic Syndrome. This was a disease that I actually acquired as a young child and was diagnosed and treated for. The way it is described is a early destruction of red blood cells which affects the Cardiovascular system. It ends up clogging the filter systems of the kidneys and then at some point could lead to kidney failure if not treated correctly.

Atypical Hemolytic Uremic Syndrome (aHUS) is a rare chronic disease, different from typical hemolytic uremic syndrome (HUS). Typical HUS is caused by bacteria, specifically E. Coli (“Hemolytic uremic syndrome (HUS)”, 2016; Noris & Remuzzi, 2010). It can be treated, and most children will have a full recovery (“Hemolytic uremic syndrome (HUS)”, 2016). aHUS can develop in two forms: familial or sporadic, that affect both children and adults, making it difficult to diagnose (Noris & Remuzzi, 2010; NORD, 2016). Atypical Hemolytic Uremic Syndrome is distinguished by three main manifestations: hemolytic anemia (destruction of RBC), thrombocytopenia (low platelets), and uremia NORD, 2016; Loirat & Fremeaux-Bacci, 2011; Biermann, 2017; Kaplan,

The clinical presentation of patients with aplastic anemia includes symptoms related to the decrease in bone marrow production of hematopoietic cells. Specific manifestations include pallor, headache, palpitations, dyspnea, fatigue, or ankle edema (Porth, 2015). Signs and symptoms of aplastic anemia may include nosebleeds and bleeding gums, frequent or prolonged infections, and pharyngeal ulcerations. Patients with aplastic anemia commonly present with symptoms of pallor, headache, palpitations, dyspnea, easy bruising and fatigue (Porth, 2015). Other symptoms include visual disturbance due to retinal hemorrhage, petechial rashes, SOB with exertion, dizziness (Porth, 2015). Patients with aplastic anemia also present with jaundice and evidence of clinical hepatitis (Porth, 2015). Obtaining work history, solvent exposure, as well as a family, environmental, and infectious disease history (Musser, 2006). The clinical presentation of

Pernicious anemia is an autoimmune disorder that prevents the body from making the intrinsic factor. It is important to know how this process works. An autoimmune disease is a disease where the body’s own immune system makes antibodies that attack its own body because it recognizes something in the body (in this case intrinsic factor) as foreign that needs to be destroyed. The antibodies attack the

For children suffering from autoimmune hemolytic anemia, therapy and treatment will be based upon the child’s age, the general health of the child, and the child’s medical record. Treatment will also depend on the extent of the anemia, the cause of the anemia, and the child's tolerance for certain medications, and potential course of the anemia. The treatment for children with autoimmune hemolytic anemia may consist of blood transfusions, corticosteroid medications, and possible surgical removal of the spleen, for children who do not respond to other treatments.